High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort
出版年份 2015 全文链接
标题
High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort
作者
关键词
-
出版物
PLoS One
Volume 10, Issue 6, Pages e0131046
出版商
Public Library of Science (PLoS)
发表日期
2015-06-30
DOI
10.1371/journal.pone.0131046
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer
- (2014) V. K. Morris et al. ANNALS OF ONCOLOGY
- Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype
- (2014) Y Zhu et al. BRITISH JOURNAL OF CANCER
- Mutational analysis and clinical correlation of metastatic colorectal cancer
- (2014) Andrea L. Russo et al. CANCER
- BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer
- (2014) Rona Yaeger et al. CANCER
- Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
- (2014) S. Venderbosch et al. CLINICAL CANCER RESEARCH
- Role ofNRASmutations as prognostic and predictive markers in metastatic colorectal cancer
- (2014) Marta Schirripa et al. INTERNATIONAL JOURNAL OF CANCER
- PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
- (2014) Lee S. Schwartzberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer
- (2013) H. Sorbye et al. ANNALS OF ONCOLOGY
- RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases
- (2013) Jean-Nicolas Vauthey et al. ANNALS OF SURGERY
- EGFR, BRAF and KRAS Status in Patients Undergoing Pulmonary Metastasectomy from Primary Colorectal Carcinoma: A Prospective Follow-Up Study
- (2013) Thomas Schweiger et al. ANNALS OF SURGICAL ONCOLOGY
- Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases
- (2013) Georgios Karagkounis et al. CANCER
- Improvement in survival of metastatic colorectal cancer: Are the benefits of clinical trials reproduced in population-based studies?
- (2013) E. Mitry et al. EUROPEAN JOURNAL OF CANCER
- FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
- (2013) F. Loupakis et al. EUROPEAN JOURNAL OF CANCER
- Associations Between Colorectal Cancer Molecular Markers and Pathways With Clinicopathologic Features in Older Women
- (2013) N.Jewel Samadder et al. GASTROENTEROLOGY
- Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
- (2013) Paul Lochhead et al. JNCI-Journal of the National Cancer Institute
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colorectal Cancers from Distinct Ancestral Populations Show Variations in BRAF Mutation Frequency
- (2013) Megan C. Hanna et al. PLoS One
- BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice: Correlations with Clinical Characteristics, and Its Impact on Patients’ Outcome
- (2013) Zacharenia Saridaki et al. PLoS One
- Colorectal cancer: a tale of two sides or a continuum?: Figure 1
- (2012) Mai Yamauchi et al. GUT
- Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
- (2012) Kjell Magne Tveit et al. JOURNAL OF CLINICAL ONCOLOGY
- BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
- (2011) T Yokota et al. BRITISH JOURNAL OF CANCER
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
- (2011) Ben Tran et al. CANCER
- Improvements in population-based survival of patients presenting with metastatic rectal cancer in the south of the Netherlands, 1992–2008
- (2011) V. E. P. P. Lemmens et al. CLINICAL & EXPERIMENTAL METASTASIS
- Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer
- (2011) Muhammad A. Khattak et al. EUROPEAN JOURNAL OF CANCER
- The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104-trial
- (2011) D.P. Modest et al. INTERNATIONAL JOURNAL OF CANCER
- Impact ofKRASandBRAFGene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer
- (2011) Timothy J. Price et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Timothy S Maughan et al. LANCET
- B Vitamins, Methionine and Alcohol Intake and Risk of Colon Cancer in Relation to BRAF Mutation and CpG Island Methylator Phenotype (CIMP)
- (2011) Eva S. Schernhammer et al. PLoS One
- Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in The Netherlands 1989-2006
- (2010) L. N. van Steenbergen et al. ANNALS OF ONCOLOGY
- KRAS analysis in colorectal carcinoma: Analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice
- (2010) Magnus Sundström et al. BMC CANCER
- Smoking, Gender, and Ethnicity Predict Somatic BRAF Mutations in Colorectal Cancer
- (2010) L. S. Rozek et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab
- (2010) Jolien Tol et al. EUROPEAN JOURNAL OF CANCER
- Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation
- (2010) Jeanne Tie et al. INTERNATIONAL JOURNAL OF CANCER
- Cigarette Smoking and Colorectal Cancer Risk by Molecularly Defined Subtypes
- (2010) David Limsui et al. JNCI-Journal of the National Cancer Institute
- Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients
- (2009) Halfdan Sorbye et al. CANCER
- KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
- (2009) Susan D. Richman et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search